Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.

PloS one - 1 Jan 2013

Ellsworth Katarzyna A, Eckloff Bruce W, Li Liang, Moon Irene, Fridley Brooke L, Jenkins Gregory D, Carlson Erin, Brisbin Abra, Abo Ryan, Bamlet William, Petersen Gloria, Wieben Eric D, Wang Liewei

Abstract excerpt

PURPOSE: FKBP51, (FKBP5), is a negative regulator of Akt. Variability in FKBP5 expression level is a major factor contributing to variation in response to chemotherapeutic agents including gemcitabine, a first line treatment for pancreatic cancer. Genetic variation in FKBP5 could influence its function and, ultimately, treatment response of pancreatic cancer. EXPERIMENTAL DESIGN: We set out to comprehensively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to Pancreatic Neoplasms

Share to Pharmacogenetics

Share to Receptors, Glucocorticoid

Share to Survival Analysis

Share to Tacrolimus Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23936393
DOI: 10.1371/journal.pone.0070216
PMCID: PMC3731355

Genes

FKBP5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.PMID 23936393Read ↗

The role of FKBP5 in cancer aetiology and chemoresistanceSemantic proximity Read ↗

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancerSemantic proximity Read ↗

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.Semantic proximity Read ↗

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.Semantic proximity Read ↗

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Semantic proximity Read ↗

FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.Semantic proximity Read ↗

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.Semantic proximity Read ↗

Differential Dynamics and Roles of FKBP51 Isoforms and Their Implications for Targeted TherapiesSemantic proximity Read ↗

Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.Semantic proximity Read ↗

Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.